🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs
755

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 755 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Page 4 of 16

  1. RO7795068, RO7795068, RO7795068, RO7795068, RO7795068, RO7795068 Placebo, RO7795068

    Hoffmann-La Roche

    Obesity or Overweight Without Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  2. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    NASH

    phase 3 small molecule active

    1 trial

  3. Retatrutide, Tirzepatide, Retatrutide, Tirzepatide, Tirzepatide, Tirzepatide, Retatrutide, Retatrutide, Retatrutide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  4. Rimonabant

    Sanofi Pasteur

    Obesity

    phase 3 small molecule terminated

    1 trial

  5. Rybelsus 7 mg tablets, Placebo (semaglutide) tablet, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  6. Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen, IcoSema 700 U/mL + 2 mg/mL PDS290

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  7. SYR-472

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    5 trials

  8. SYR-472

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  9. Saxagliptin

    AstraZeneca

    Diabetes

    phase 3 small molecule completed

    1 trial

  10. Semaglutide B 1.34 mg/mL PDS290 3.0 mL, Wegovy 2.4 mg solution for injection in pre-filled pen, Pre-filled syringe (glass) in a pre-filled pen: Semaglutide placebo Ia DV3396 pen-injector, 0.5 mL Semaglutide placebo Ib DV3396 pen-injector, 0.75 mL, Semaglutide B 0.68 mg/mL PDS290 1.5 mL, Semaglutide D 1.0 mg/mL DV3396, Semaglutide D 2.0 mg/mL DV3396, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Semaglutide B 3.2 mg/mL PDS290 3.0 mL

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  11. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity Associated With Defects in Leptin-melanocortin Pathway

    phase 3 small molecule active

    2 trials

  12. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity

    phase 3 small molecule active

    1 trial

  13. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Leptin Receptor Deficiency Obesity

    phase 3 small molecule completed

    1 trial

  14. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 3 small molecule active

    3 trials

  15. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Pro-opiomelanocortin (POMC) Deficiency Obesity

    phase 3 small molecule completed

    1 trial

  16. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus (T1DM)

    phase 3 small molecule completed

    1 trial

  17. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  18. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  19. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Nephropathies

    phase 3 small molecule active

    1 trial

  20. Sotagliflozin (SAR439954)

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    4 trials

  21. Sotagliflozin Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes (T1D)

    phase 3 small molecule active

    1 trial

  22. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    diabetic foot syndrome, lower limb ischemia

    phase 3 small molecule active

    1 trial

  23. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 3 small molecule active

    3 trials

  24. TAK-559

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  25. TAK-559 and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  26. TAK-559 and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  27. TAK-559 and metformin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  28. TAK-875

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    4 trials

  29. TAK-875

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  30. TAK-875

    Takeda

    Diabetic Patients

    phase 3 small molecule completed

    1 trial

  31. TAK-875

    Takeda

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  32. TAK-875

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  33. TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, Placebo to match LY, Retatrutide, Placebo to match LY

    Eli Lilly Co.

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  34. TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Placebo to match LY3298176, TIRZEPATIDE, TIRZEPATIDE

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  35. Tang-min Lin pill

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  36. Teplizumab

    Sanofi Pasteur

    Type 1 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  37. Teplizumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Nutritional and metabolic diseases

    phase 3 small molecule active

    1 trial

  38. Tesaglitazar

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  39. Tesaglitazar 0.5 or 1 mg

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  40. Tirzepatide

    Eli Lilly and Company

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  41. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Mirikizumab, to match Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide

    Eli Lilly Co.

    Obesity or Overweight, Crohn’s Disease

    phase 3 small molecule active

    1 trial

  42. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Placebo to match LY3298176 injection

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  43. Tradipitant

    Lacuna Pharma Pty Ltd

    Idiopathic or diabetic gastroparesis with moderate to severe nausea.

    phase 3 small molecule active

    1 trial

  44. Trelagliptin 25 mg

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  45. Trichosanthes root

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  46. Trulicity 0.75 mg solution for injection in pre-filled pen

    The George Institute

    Metabolic syndrome in patients on the waiting list for kidney transplantation, Metabolic syndrome in patients on the waiting list for kidney transplantation

    phase 3 small molecule active

    1 trial

  47. Trulicity 0.75 mg solution for injection in pre-filled pen

    The George Institute

    Preventive treatment of post-kidney transplant diabetes

    phase 3 small molecule active

    1 trial

  48. UDCA

    The First People's Hospital of Lianyungang

    Diabetes Mellitus

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

755 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.